September 19, 2019 / 6:42 AM / a month ago

BRIEF-Nanobiotix Announces Phase I Study Results On NBTXR3

Sept 19 (Reuters) - NANOBIOTIX SA:

* ANNOUNCED ON WEDNESDAY PHASE I STUDY RESULTS SHOW FIRST-IN-CLASS NBTXR3 COULD PRESENT AS A VALUABLE OPTION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA OR LIVER METASTASIS

* NBTXR3 ACTIVATED BY STEREOTACTIC BODY RADIATION THERAPY (SBRT) WAS SAFE AND WELL-TOLERATED AT EACH OF THE FOUR (4) DOSE ESCALATION LEVELS

* NBTXR3 REMAINED IN THE TUMOR FROM INJECTION THROUGH THE END OF RADIATION THERAPY WITHOUT LEAKAGE TO SURROUNDING HEALTHY TISSUE

* STUDY SHOWED POSITIVE SIGNS OF EFFICACY FOR HEPATOCELLULAR CARCINOMA (HCC) PATIENTS, AS EVERY EVALUABLE PATIENT RESPONDED AND OVER HALF (62.5%) REACHED COMPLETE RESPONSE

* GIVEN THAT THE SAFETY PROFILE WAS VERY GOOD, A 5TH DOSE ESCALATION LEVEL HAS BEEN ADDED TO THE TRIAL AND IS CURRENTLY RECRUITING

* THESE RESULTS, HCC PARTICULARLY, ARE SIGNIFICANT AS THEY MAY WIDEN THE SCOPE OF INDICATIONS NBTXR3 CAN TREAT AND BOLSTER THE COMPANY’S GO-TO-MARKET STRATEGY

* HAFNIUM OXIDE NANOPARTICLES ACTIVATED BY SBRT FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA AND LIVER METASTASIS: A PHASE I/II TRIAL

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below